Australia markets open in 22 minutes
  • ALL ORDS

    7,707.20
    +102.00 (+1.34%)
     
  • AUD/USD

    0.7172
    +0.0054 (+0.76%)
     
  • ASX 200

    7,405.40
    +91.50 (+1.25%)
     
  • OIL

    72.65
    +0.60 (+0.83%)
     
  • GOLD

    1,784.10
    -0.60 (-0.03%)
     
  • BTC-AUD

    70,708.51
    -121.81 (-0.17%)
     
  • CMC Crypto 200

    1,320.56
    +15.44 (+1.18%)
     

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

·2-min read
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

After the Food and Drug Administration paused Allogene Therapeutics' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. The FDA's intervention appeared to spur trading by ARK Invest in Beam Therapeutics (NASDAQ: BEAM), Intellia Therapeutics (NASDAQ: NTLA), and Schrödinger (NASDAQ: SDGR).

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting